HAVE INFLIXIMAB DISCOUNTED PRICES IN NORWAY HAD AN IMPACT ON PRICES AROUND THE WORLD?
Author(s)
Reinaud F1, Ando G2
1IHS Life Sciences, Paris, France, 2IHS Life Sciences, London, UK
OBJECTIVES: Following the availability of biosimilars of Remicade (infliximab, Janssen Cilag) - which target severe pathologies - a national tender was launched in Norway in order to negotiate discounts. Orion, manufacturing the biosimilar Remsima, won the national tender by offering a 72% discount compared with Remicade in February 2015. Hospira, manufacturing the biosimilar Inflectra, offered a 51% discounts. Given the extent of the discounts and wide publicity of the prices, the goal of this survey was to assess if list prices of infliximab were impacted in Norway as well as in countries using Norway in their International Reference Pricing (IRP) rules. METHODS: Ex-manufacturer list price changes over time for Remicade and biosimilars of infliximab were analysed in Norway as well as in countries using Norway in their IRP rules and for which list prices are available, namely: Denmark, Finland, Iceland, Poland and Slovenia. RESULTS: Our results show that while the tender led to significant discounts, list prices (since biosimilars are available) of either the biologic product or biosimilars have remained constant in Norway. Additionally, prices have remained constant in all countries using Norway in their IRP rules except for Iceland, where prices have regularly decreased. The change is however not linked to IRP rules. CONCLUSIONS: The research indicates that prices around the world for Remicade and infliximab biosimilars have not been impacted by price changes in Norway. Whilst the new prices generated significant global attention, they have not been formally incorporated into pricing negotiations elsewhere, at least for the time being. This is partly because certain countries may not have had time to conduct IRP against Norwegian prices yet, but also because the list prices remain unchanged, and IRP at the discount level remains rare.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PHP23
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes
Disease
Multiple Diseases